PANews October 21 news, according to an official OpenAI announcement, OpenAI has acquired Orchestra Bio, a drug R&D collaboration platform. The platform helps biopharmaceutical teams coordinate complex drug development processes, allowing scientists and project leads to delegate the monitoring and tracking of research and trials to AI agents. OpenAI stated that it will integrate Orchestra's team and technology with Rosalind, its life sciences research AI model and tool, to help new therapies reach patients faster.
OpenAI acquires drug R&D collaboration platform Orchestra Bio
Verwandte Nachrichten
Finanzierungswoche | Kalshi schließt 1 Milliarde US-Dollar Series-G-Finanzierung ab, angeführt von Sequoia Capital und Wellington Management.
Kalshi hat eine Series-G-Finanzierungsrunde in Höhe von 1 Milliarde US-Dollar abgeschlossen und erreichte eine Post-Money-Bewertung von 40 Milliarden US-Dollar,...